Global Corporate Council

NCCN gratefully acknowledges the support and commitment of the following companies to the improvement of the treatments available to the patients whom we all serve. We also appreciate the recognition of NCCN's necessary autonomy in all decision-making regarding the conclusions, recommendations and outcomes of NCCN programs and resources.

The NCCN Global Corporate Council is an important resource for the development and expansion of NCCN programs and resources.

More information will be provided on the next NCCN Global Corporate Council Meeting as it becomes available.

NCCN offers membership into the NCCN Global Corporate Council to significantly enhance collaborative efforts between pharmaceutical and biotechnical companies and NCCN, and thus better serve patients. NCCN gratefully acknowledges the support and commitment of the following companies through NCCN Global Corporate Council:

  • amgen118
  • astellas118
  • astraZen118
  • bayer118
  • BeiGene-118x40
  • daiichi-sankyo-118x36
  • BoehringerGlobal118
  • genomic-118x24
  • incyte-118x85
  • janssen118
  • merck-kgaa118x40
  • myriad118
  • novarts118
  • oncopeptides-118x118
  • regeneron118
  • roche118
  • sanofi-118
  • Seagen118
  • takeda-118x59

NCCN is grateful for the support of our US NCCN Corporate Council Members. To view a full list of NCCN Corporate Council Members, click here.